Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value

Viatris Inc. (NASDAQ:VTRS) is one of the dirt cheap stocks to buy now. On February 26, Viatris reported a steady financial performance for the full-year 2025, generating $14.3 billion in total revenue, a 2% increase over the previous year when excluding Indore-related impacts. The company achieved an adjusted EBITDA of $4.2 billion and an adjusted EPS of $2.35, supported by $2.2 billion in free cash flow.

The company’s initiatives were marked by significant regulatory progress, including five positive Phase III readouts and the completion of 60 regional transactions, such as the acquisition of Aculys Pharma in Japan. For 2026, Viatris anticipates total revenue and adjusted EBITDA growth of approximately 2%, with new product revenue expected to contribute between $450 million and $550 million.

To support long-term competitiveness, a strategic review identified $650 million in gross cost savings to be realized through 2029, with a portion earmarked for reinvestment. Despite these gains, Viatris Inc. (NASDAQ:VTRS) faces headwinds, including uncertain FDA reinspection timing for its Indore facility and anticipated gross margin declines due to losses of exclusivity and product mix shifts.

Viatris Inc. (NASDAQ:VTRS), together with its subsidiaries, operates as a healthcare company internationally. It has four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.